Angiogenesis enhances factor IX delivery and persistence from retrievable human bioengineered muscle implants (Q45858842)

17 December 2017

title

Angiogenesis enhances factor IX delivery and persistence from retrievable human bioengineered muscle implants (English)

1 reference

17 December 2017

Lieven Thorrez

1

0 references

Nico Callewaert

object named as

Nico Callewaert

3

0 references

author name string

Herman Vandenburgh

2

1 reference

17 December 2017

Nico Mertens

4

1 reference

17 December 2017

Janet Shansky

5

1 reference

17 December 2017

Lin Wang

6

1 reference

17 December 2017

Jef Arnout

7

1 reference

17 December 2017

Désiré Collen

8

1 reference

17 December 2017

Marinee Chuah

9

1 reference

17 December 2017

Thierry Vandendriessche

10

1 reference

17 December 2017

publication date

5 June 2006

1 reference

17 December 2017

published in

Molecular Therapy

1 reference

17 December 2017

volume

14

1 reference

17 December 2017

issue

3

1 reference

17 December 2017

page(s)

442-451

1 reference

17 December 2017

Preclinical and clinical gene therapy for haemophilia

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.03.019

Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.03.019

Therapeutic factor VIII levels and negligible toxicity in mouse and dog models of hemophilia A following gene therapy with high-capacity adenoviral vectors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.03.019

Nonviral transfer of the gene encoding coagulation factor VIII in patients with severe hemophilia A.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.03.019

Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.03.019

LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.03.019

Gene therapy for hemophilia A: production of therapeutic levels of human factor VIII in vivo in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.03.019

Posttranslational modifications of recombinant myotube-synthesized human factor IX.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.03.019

Safety and efficacy of factor IX gene transfer to skeletal muscle in murine and canine hemophilia B models by adeno-associated viral vector serotype 1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.03.019

Gene therapy via primary myoblasts: long-term expression of factor IX protein following transplantation in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.03.019

Systemic delivery of human growth hormone by injection of genetically engineered myoblasts.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.03.019

Extended Amplification In Vitro and Replicative Senescence: Key Factors Implicated in the Success of Human Myoblast Transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.03.019

Regenerative potential of human skeletal muscle during aging

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.03.019

The fate of individual myoblasts after transplantation into muscles of DMD patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.03.019

Skeletal muscle satellite cell transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.03.019

Tissue-engineered skeletal muscle organoids for reversible gene therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.03.019

Mechanical stimulation improves tissue-engineered human skeletal muscle

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.03.019

Lentiviral vectors containing the human immunodeficiency virus type-1 central polypurine tract can efficiently transduce nondividing hepatocytes and antigen-presenting cells in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.03.019

Phenotypic correction of factor IX deficiency in skin fibroblasts of hemophilic dogs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.03.019

Bone marrow stromal cells as a genetic platform for systemic delivery of therapeutic proteins in vivo: human factor IX model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.03.019

Tissue-engineered human bioartificial muscles expressing a foreign recombinant protein for gene therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.03.019

VEGF gene therapy: stimulating angiogenesis or angioma-genesis?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.03.019

Use of blood outgrowth endothelial cells for gene therapy for hemophilia A.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.03.019

Sustained expression of high levels of human factor IX from human cells implanted within an immunoisolation device into athymic rodents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.03.019

Sustained and therapeutic delivery of factor IX in nude haemophilia B mice by encapsulated C2C12 myoblasts: concurrent tumourigenesis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.03.019

Characterisation of two differently processed forms of human recombinant factor IX synthesised in CHO cells transformed with a polycistronic vector

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.03.019

Molecular basis of hemophilia B: a defective enzyme due to an unprocessed propeptide is caused by a point mutation in the factor IX precursor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.03.019

Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liver-directed gene therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.03.019

Carbohydrate-Specific Receptors of the Liver

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.03.019

Recombinant coagulation factor IX: glycosylation analysis and in vitro conversion into human-like sialylation pattern.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.03.019

The safety and efficacy of recombinant human blood coagulation factor IX in previously untreated patients with severe or moderately severe hemophilia B.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.03.019

Expression of human factor IX in mice after injection of genetically modified myoblasts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.03.019

Long-term persistence of human bone marrow stromal cells transduced with factor VIII-retroviral vectors and transient production of therapeutic levels of human factor VIII in nonmyeloablated immunodeficient mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.03.019

Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.03.019

Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.03.019

Gene transfer by lentiviral vectors is limited by nuclear translocation and rescued by HIV-1 pol sequences

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.03.019

Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.03.019

Increase in percutaneous muscle biopsy yield with a suction-enhancement technique

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.03.019

Efficient selection for high-expression transfectants with a novel eukaryotic vector

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.03.019

Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.03.019

Recombinant vascular endothelial growth factor secreted from tissue-engineered bioartificial muscles promotes localized angiogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.03.019

10.1016/J.YMTHE.2006.03.019

7 January 2021

Identifiers

DOI

1 reference

17 December 2017

PubMed ID

16750937

1 reference

17 December 2017